Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.
The company reported fiscal year 2023 losses of 96 cents per share, compared to losses of $3.78 per share from the prior year. Taysha reported it had $143.9 million in cash and cash equivalents on Dec. 31, 2023.
The company also provided clinical updates including the completed dosing in cohort one of its REVEAL Phase 1/2 adolescent and adult trial and the expansion of the ongoing trial in Canada into the U.S. and initiated site activation.
Taysha Gene Therapies shares jumped 27.1% to $2.86 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
- ETAO International Co., Ltd. (NASDAQ: ETAO) shares rose 200.4% to $0.4296 in pre-market trading. The company announced a reverse stock split.
- Oblong, Inc. (NASDAQ: OBLG) rose 48.2% to $0.20 in pre-market trading after the company reported financial results for fourth quarter 2023 and issued a business update.
- BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) climbed 44% to $0.0288 in pre-market trading after falling 15% on Tuesday. Aegis Capital acted as Sole bookrunner on a $7.0 million underwritten public offering for BYND Cannasoft Enterprises Inc.
- Mangoceuticals, Inc. (NASDAQ: MGRX) shares rose 40.5% to $0.2698 in pre-market trading after gaining around 4% on Tuesday.
- EZFill Holdings Inc. (NASDAQ: EZFL) gained 18% to $1.90 in pre-market trading after falling 9% on Tuesday.
- SCWorx Corp. (NASDAQ: WORX) rose 16.9% to $3.32 in pre-market trading after surging around 54% on Tuesday.
- BitFuFu Inc. (NASDAQ: FUFU) shares gained 11.7% to $6.03 in pre-market trading after gaining 32% on Tuesday.
- Canopy Growth Corporation (NASDAQ: CGC) gained 14.4% to $4.38 in pre-market trading. VP Kamala Harris recently urged the DEA to reschedule marijuana.
- Getty Images Holdings, Inc. (NYSE: GETY) shares rose 14% to $5.36 in pre-market trading. Getty Images recently reported better-than-expected fourth-quarter revenue results and issued FY24 revenue guidance.
- Ontrak, Inc. (NASDAQ: OTRK) dipped 20.5% to $0.35 in pre-market trading after jumping over 131% on Tuesday.
- Momentus Inc. (NASDAQ: MNTS) fell 19.1% to $0.4803 pre-market trading, reversing after spiking 17% on Tuesday following a US patent grant.
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) fell 14.8% to $4.55 in pre-market trading. Aquestive Therapeutics priced its $75 million underwritten public offering of 16,666,667 common shares at $4.50 per share.
- Verb Technology Company, Inc. (NASDAQ: VERB) fell 14.2% to $0.3309 pre-market trading after surging 7% on Tuesday. The company on Friday announced its Market.live launched Facebook and Instagram social shopping technology integration. Also, the company announced it added 100 more retail brands to its livestream social shopping platform.
- Harrow, Inc. (NASDAQ: HROW) fell 14.6% to $9.09 in pre-market trading after posting weaker-than-expected fourth-quarter results.
- NuScale Power Corporation (NYSE: SMR) shares tumbled 6.8% to $6.13 in pre-market trading. NuScale Power shares dipped around 35% on Tuesday after Wells Fargo downgraded the stock from Equal-Weight to Underweight and lowered its price target from $7.50 to $4.50.
- CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) declined 6.4% to $2.25 in pre-market trading after surging 14% on Tuesday.
- Clearmind Medicine Inc. (NASDAQ: CMND) shares fell 6.2% to $1.21 in pre-market trading. On Tuesday, Clearmind Medicine announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.
- MaxCyte, Inc. (NASDAQ: MXCT) shares tumbled 5.8% to $4.20 after gaining 7% on Tuesday. MaxCyte, last week, reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
- Society Pass Incorporated (NASDAQ: SOPA) shares fell 5% to $0.1456 in pre-market trading.
Now Read This: Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.